Showing posts with label Microbes and More. Show all posts
Showing posts with label Microbes and More. Show all posts

Daily Science Journal (Feb. 1, 2008) — Scientists at Saint Louis University and the University of Alabama at Birmingham have uncovered important new information about a key protein that allows viruses such as smallpox to replicate and wreak havoc on the immune system.

The findings further our understanding of how the pox family of viruses work to subvert the immune system, the researchers say. They also believe their work could one day be used to develop new drugs to combat a variety of inflammatory and immunological disorders, including rheumatoid arthritis and some forms of heart disease.

The paper* describes the structure and actions of a powerful substance called interferon-gamma binding protein, which is notorious for the role it plays in helping the poxviruses to replicate. The research explores the interferon-gamma binding protein found in the mousepox virus -- one of the family of viruses that also includes smallpox, monkeypox and cowpox.


"Cracking open and describing the structure and actions of interferon-gamma binding protein is incredibly exciting, given the important role this substance plays in subverting the immune system," said Mark Buller, Ph.D., professor of microbiology and immunology at the Saint Louis University School of Medicine and one of the study's authors. "This breakthrough is something that many others have tried and failed to achieve."

Normally when a virus enters the bloodstream, the immune system responds by producing a substance called interferon-gamma, which assists the development of the immune response that's responsible for ridding the body of the virus.

Poxviruses, however, all come encoded with a potent weapon to evade the immune system: interferon-gamma binding protein. As its name implies, the protein literally binds to interferon-gamma and immobilizes it, preventing it from marshalling the immune system's defenses. The poxvirus is then able to replicate and cause immense damage.

The research describes how interferon-gamma binding protein looks and behaves on the molecular level during this process, something not previously understood.

"The poxviruses are able to evade the immune system very skillfully," Buller said, "so we wanted to identify exactly how these viruses work -- what makes them so effective and efficient."

Buller added that the findings have great potential for use in developing drugs that target immunological and inflammatory disorders, including a type of heart disease called atherosclerosis (sometimes referred to as hardening of the arteries), inflammatory bowel diseases (such as Crohn's disease and ulcerative colitis) and rheumatoid arthritis.

Of all the poxviruses, smallpox in particular has played a gruesome role in human history. The virus is estimated to have caused between 300 million and 500 million deaths in the 20th century alone. Though smallpox was declared officially eradicated in 1979, many experts fear that clandestine samples of the virus may have survived -- thus making it a major bioterrorism concern.

"The damage that the smallpox virus has done to mankind is horrific and enormous, which is why we think it's so important to understand more about the poxviruses and how they operate," Buller said. "The more knowledge we have, the better we should be able to cope with other major viruses and diseases in the future."

Buller pointed to co-author Tony Nuara as being critical to the team's success in understanding more about interferon-gamma binding protein. Nuara, now a fourth-year student at Saint Louis University School of Medicine, was working on his Ph.D. in molecular microbiology when taking part in the research effort.

"Without Tony, this research wouldn't have happened," Buller said. "He solved huge numbers of problems and figured out some answers to puzzling questions that previously had no answer."

Mark R. Walter, Ph.D., associate professor of microbiology at the University of Alabama at Birmingham and the paper's senior author, also noted the efforts of co-authors Sung Il Yoon, Ph.D., Brandi C. Jones, Naomi J. Logsdon and Leigh J. Walter, all of whose work contributed to determining the three-dimensional structure of the binding protein.

"The structure provides a visual blueprint to guide our future studies on interferon-gamma binding protein, which one day may be used to prevent inflammatory disease," Mark Walter said. "This is clearly a notable achievement."

*The research has been published in an early online edition of the Proceedings of the National Academy of Sciences. Jill M. Schriewer of Saint Louis University was also a co-author of the study.

The research was funded by grants from the National Institutes of Health, the UAB Center for Emerging Infections and Emergency Preparedness, and the American Heart Association.

Adapted from materials provided by Saint Louis University, via EurekAlert!, a service of AAAS.



Read the rest of this entry »

Daily Science Journal (Jan. 5, 2008) — Most people wouldn't consider anthrax toxin to be beneficial, but this bacterial poison may someday be an effective cancer therapy. Anthrax toxin has actually been shown to be fairly selective in targeting melanoma cells, although the risk of non-cancer toxicity prevents any clinical use.

After binding to cell surface markers, the MMP-activated PA protein (PA-L1) is cleaved by surface associated MMPs, releasing the PA20 fragment. The remaining receptor-bound fragment rapidly oligomerizes to form a heptamer. Up to three molecules of anthrax lethal factor (LF) bind to the heptamer, which is then internalized. Once inside the cell, the complex encounters an acidic environment, which induces a conformational change and allows the LF to enter the cytosol. LF released into the cytosol shuts down multiple signaling pathways, leading to inhibition of tumor angiogenesis and human melanoma cell death. (Credit: Image created by Drs. Shihui Liu, Mahtab Moayeri, and Stephen H. Leppla)


To develop a better and safer treatment, Stephen Leppla and colleagues created a mutated antrax toxin that could only be turned on by matrix metalloproteinases (MMP), proteins that are overproduced only in cancer cells.

When they tested this mutated toxin in mice, the researchers observed that 100% of the animals tolerated a dose that would be lethal for the natural toxin. The MMP-toxin was also better at killing melanoma tumors than natural toxin, due to its higher specificity and longer half-life in the blood.

Even better, Leppla and colleagues saw that MMP-toxin was not limited to melanoma, and could also kill other tumors like colon and lung. This more widespread activity was due to the toxin's ability to inhibit angiogenesis, or the formation of new blood vessels.

These encouraging mouse results suggest that modified anthrax toxin could be clinically viable, and this potent killer might someday be put to good use.

Adapted from materials provided by American Society for Biochemistry and Molecular Biology, via EurekAlert!, a service of AAAS.



Read the rest of this entry »

Daily Science Journal (Nov. 12, 2007) — Scientists from the Max Planck Institute for Infection Biology in Berlin discovered why lung, but not skin, anthrax infections are lethal. As reported in the newest issue of PloS Pathogen (November 2007) Neutrophils, a form of white blood cells, play a key role in anthrax infections.

A human neutrophil takes up Bacillus anthracis. (Image: MPI for Infection Biology)

They can kill Bacillus anthracis by producing a protein called alpha-defensin. This discovery might now pave the way towards the development of new therapiesfor the fatal lung form of anthrax.


Bacillus anthracis is the causative agent of anthrax. What makes Bacillus anthracis especially dangerous is that these bacteria can form spores. The spores are extremely resistant against environmental stress and can survive for years.Infection with Bacillus anthracis can take place either via the lung or through the skin. Interestingly, the lung form of anthrax is almost always fatal, whereas skin infections remain localized and are rarely lethal. In contrast to the lung form, the skin form of anthrax can be treated without problems and most patients recover. During the past few years, Bacillus anthracis has also been used as a weapon for bioterrorism. Anthrax spores were sent in envelopes and inhaled and resulted in the death of 5 people in the USA.

The findings of the lab of Arturo Zychlinsky now help clarifying why the skin form is harmless in contrast to the lung form. After a skin infection with Bacillus anthracis, neutrophils are recruited to the site of infection. Neutrophils are white blood cells that can identify and kill microbes. In the skin, neutrophils take up the spores, which germinate inside the neutrophil to a vegetative ("growing") bacterium. This vegetative bacterium is then attacked and killed within the neutrophil. The scientists succeeded in identifying the substance responsible for the killing of the bacteria. After fractionation of neutrophil components only one protein remained which is sufficient for killing Bacillus anthracis: alpha-defensin

This mechanism is not effective in the lung form of anthrax. Here, the number of neutrophils recruited to the site of infection is known to be low, and insufficient to kill bacteria. Thus, inhaled spores can germinate and spread through the organism. The scientists in Berlin now hope that their discovery will help to develop new drugs against the lung form of anthrax. There might be the possibility that the inhalation of alphadefensin might kill vegetative bacteria in the lung and prevent dissemination.

Adapted from materials provided by Max Planck Society.




Read the rest of this entry »

Daily Science Journal (Nov. 8, 2007) — Amid continuing concerns that anthrax might be used as a bioterrorism weapon, government researchers report development of a faster, more sensitive blood test for detecting the deadly toxins produced by the anthrax bacterium, Bacillus anthracis. The test produces results in only 4 hours and could save lives by allowing earlier detection of infection, they say.

Anthrax spores as photographed under an electron microscope. (Credit: Courtesy of Centers for Disease Control and Prevention)

Standard identification of anthrax (Bacillus anthracis) infection relies on a combination of time-consuming steps, including cell culture and gene amplification, which can take several days to provide a diagnosis and have limitations for detecting early stages of infection. Early diagnosis is critical for effective treatment of pulmonary or inhalation anthrax, the most deadly form.


John R. Barr and colleagues in a multi-center team effort used a form of mass spectrometry to detect the presence of 'lethal factor,' the key toxin produced by the anthrax bug, in the blood of monkeys with inhalation anthrax.

The method took only four hours to identify the toxin and detected it at very low levels, demonstrating its potential for early detection of infection, the researchers say. The new method also shows promise as a research tool for providing a better understanding of the anthrax infection cycle and for evaluating the effectiveness of different therapies and methods to fight infections.

The article "Detection and Quantification of Anthrax Lethal Factor in Serum by Mass Spectrometry" is scheduled for publication in the Nov. 22 issue of ACS' Analytical Chemistry.

Adapted from materials provided by American Chemical Society, via EurekAlert!, a service of AAAS.




Read the rest of this entry »

Daily Science Journal (Oct. 19, 2007) — A newly identified antibody capable of neutralizing the inhalation anthrax toxin in rabbits and monkeys may offer an alternative method of preventing and treating infection in humans say US researchers. Their findings appear in the October 2007 issue of the journal Infection and Immunity.

The intentional use of Bacillus anthracis, the causative agent of anthrax, continues to pose serious threat as a bioterrorism or biowarfare agent. Although vaccines currently available are highly effective, multiple doses are required therefore necessitating antibiotic therapy for those individuals exposed prior to scheduled completion.


Monoclonal antibodies (MAb) are derived from one clone of cells, recognize only one antigen (the protective antigen (PA) component of the anthrax toxin combines with the lethal factor for cell entry) and are described as highly specific and purified. In the study the fully human MAb (now recognized at MAb 1303) was selected after neutralizing the anthrax toxin in transgenic mice. MAb 1303 was then found to offer effective postsymptomatic treatment in rabbits exposed to aerosolized anthrax spores as well as serve as a protective agent in monkeys challenged with aerosolized anthrax spores following a single intramuscular injection.

"Selection of an anti-PA MAb by using a functional assay that is a surrogate for protection has resulted in the identification of a fully human MAb with potent activity in vivo and uncovered a previously unrecognized mechanism of antibody-mediated toxin neutralization that is important for currently used anthrax vaccines," say the researchers.

(L. Vitale, D. Blanset, I. Lowy, T. O'Neill, J. Goldstein, S.F. Little, G.P. Andrews, G. Dorough, R.K. Taylor, T. Keler. 2006. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infection and Immunity, 74.10: 5840-5847.)

Adapted from materials provided by American Society For Microbiology.



Read the rest of this entry »

Daily Science Journal (Jul. 23, 2007) — Scientists have identified a chemical that could be used as a new drug against anthrax.

Anthrax is a deadly disease caused by spores that germinate into bacteria, which then release a deadly toxin. Spores that are inhaled by animals or people germinate in the lungs to form bacteria, which then spread throughout the body, releasing the toxin and triggering the disease. Since spore germination is needed to cause infection, preventing germination is a potentially efficient way to stop the infection.


Jurgen Brojatsch, Ernesto Abel-Santos, and colleagues identified seven chemicals that block the germination of cultured anthrax spores. They also showed that one of these compounds, 6-thioguanosine, blocked the spores' germination inside mammalian cells, thus blocking anthrax infection. The scientists are now planning to test 6-thioguanosine in mice infected with the anthrax bacterium. This compound is a known anticancer agent with well-studied pharmacological properties, which could help save time and money if it is used in clinical trials.

Article: "Identification of an in Vivo Inhibitor of Bacillus anthracis Spore Germination" by Monique Akoachere, Raynal C. Squires, Adel M. Nour, Ludmyl Angelov, Jurgen Brojatsch, and Ernesto Abel-Santos

Adapted from materials provided by American Society for Biochemistry and Molecular Biology, via EurekAlert!, a service of AAAS.




Read the rest of this entry »